Skip to main navigation

Investor Navigation

Overview
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials
- SEC Filings
Governance
IR Resources

Press Releases

Year

09 Nov '2023

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

31 Oct '2023

Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76

27 Sep '2023

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

09 Aug '2023

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

01 Aug '2023

Context Therapeutics to Participate in Two August 2023 Investor Conferences

10 May '2023

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

03 Apr '2023

Context Therapeutics to Participate in Two April 2023 Investor Conferences

22 Mar '2023

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

15 Mar '2023

Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

06 Feb '2023

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 13

Investor Tools

Print Page
RSS Feeds
Search

Request Email Alerts

© 2023 Context Therapeutics Inc. All rights reserved.